307 related articles for article (PubMed ID: 24702090)
1. Multidrug-resistant tuberculosis in Western Australia, 1998-2012.
Francis JR; Blyth CC; Colby S; Fagan JM; Waring J
Med J Aust; 2014 Apr; 200(6):328-32. PubMed ID: 24702090
[TBL] [Abstract][Full Text] [Related]
2. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013-2017.
Okethwangu D; Birungi D; Biribawa C; Kwesiga B; Turyahabwe S; Ario AR; Zhu BP
BMC Infect Dis; 2019 May; 19(1):387. PubMed ID: 31064332
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant tuberculosis in the Northern Territory: A 10-year retrospective case series.
Judge D; Krause V
Commun Dis Intell Q Rep; 2016 Sep; 40(3):E334-E339. PubMed ID: 28278406
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
[TBL] [Abstract][Full Text] [Related]
6. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N
PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848
[TBL] [Abstract][Full Text] [Related]
7. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
8. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
9. Drug resistant tuberculosis in Saudi Arabia: an analysis of surveillance data 2014-2015.
Al Ammari M; Al Turaiki A; Al Essa M; Kashkary AM; Eltigani SA; Ahmed AE
Antimicrob Resist Infect Control; 2018; 7():12. PubMed ID: 29387346
[TBL] [Abstract][Full Text] [Related]
10. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
Liu Z; Shilkret KL; Finelli L
Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705
[TBL] [Abstract][Full Text] [Related]
12. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant tuberculosis in Australia, 1998-2012.
Francis JR; Manchikanti P; Blyth CC; Denholm J; Lowbridge C; Coulter C; Donnan E; Stapledon R; Krause VL; Waring J
Int J Tuberc Lung Dis; 2018 Mar; 22(3):294-299. PubMed ID: 29471907
[TBL] [Abstract][Full Text] [Related]
14. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
[TBL] [Abstract][Full Text] [Related]
15. Burden of Multidrug Resistant Mycobacterium tuberculosis Among New Cases in Al-Madinah Al-Monawarah, Saudi Arabia.
Elhassan MM; Hemeg HA; Elmekki MA; Turkistani KA; Abdul-Aziz AA
Infect Disord Drug Targets; 2017; 17(1):14-23. PubMed ID: 27848902
[TBL] [Abstract][Full Text] [Related]
16. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance among persons with tuberculosis in California, 1994-2003.
Granich RM; Oh P; Lewis B; Porco TC; Flood J
JAMA; 2005 Jun; 293(22):2732-9. PubMed ID: 15941802
[TBL] [Abstract][Full Text] [Related]
18. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Jiang RH; Xu HB; Li L
Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
[TBL] [Abstract][Full Text] [Related]
19. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
